Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026997 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis
A Phase 2 study, sponsored by CinDome Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT04026997: Clinical Trial Phase 2 study, sponsored by CinDome Pharma.
NCT04026997 is a Phase 2 study that was terminated before completion, run by CinDome Pharma. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04026997, a Phase 2 study, was terminated before completion, sponsored by CinDome Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
Primary Outcome
The GEBT is a nonradioactive, noninvasive, orally administered test for measuring the rate of solid phase gastric emptying (GE), after consumption of a standardized 13C-enriched meal. GEBT T1/2 is the time for half of the ingested meal to leave the stomach. It is reported using kPCD, a mathematical expression of a test subject's 13CO2 excretion rate per minute at any measurement time t relative to the dose of 13C contained in the test meal.
Interventions
- DRUG Placebo
- DRUG CIN-102 Dose 1
- DRUG CIN-102 Dose 2
- DRUG CIN-102 Dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2019-09-11 |
| Est. Completion | 2020-12-17 |
| Phase | Phase 2 |
Why NCT04026997 stopped before completion
NCT04026997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04026997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04026997 about?
NCT04026997 is a clinical study titled "A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis". This is a randomized, double-blind, placebo-controlled Phase 2A study to evaluate safety, efficacy, PK, and dose response of oral CIN-102 in adults with idiopathic and diabetic gastroparesis. The study will assess three oral doses of CIN-102 versus placebo in three separate cohorts.
What is the current status of trial NCT04026997?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2019-09-11. Estimated completion is 2020-12-17.
What interventions are being tested in trial NCT04026997?
The interventions under investigation include: Placebo (DRUG), CIN-102 Dose 1 (DRUG), CIN-102 Dose 2 (DRUG), CIN-102 Dose 3 (DRUG).
Who is sponsoring clinical trial NCT04026997?
This trial is sponsored by CinDome Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04026997's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI